European Congress of Rheumatology 2024 (EULAR 2024)

The JAK inhibitor upadacitinib brought sustained remission in the first 52 weeks of the phase III SELECT-GCA study of patients with new-onset or relapsing giant cell arteritis (GCA).

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

Treatment with ixekizumab resulted in almost 90 percent of children with active juvenile psoriatic arthritis (JPsA) or enthesitis-related arthritis (ERA) achieving an ACR30* response by week 16, according to the ongoing COSPIRIT-JIA trial presented at EULAR 2024.

The investigational monoclonal antibody nipocalimab helped reduce the intensity of Sjögren’s disease in adults in the phase II DAHLIAS trial.

Two years of treatment with the monoclonal IgG1 antibody bimekizumab led to minimal spinal radiographic progression in patients with radiographic axial spondyloarthritis (r-axSpA) in the open-label extension (OLE) of the phase III BE MOBILE 2 study.